西洛司特治疗慢性阻塞性肺疾病的临床疗效观察

Clinical Curative Observation of Cilomilast Treatment on COPD

观察西洛司特治疗慢性阻塞性肺疾病(COPD)的临床疗效。选择2017年9月—2019年6月在武警黑龙江总队医院治疗的66例COPD患者,随机分为常规治疗的普通组与西洛司特治疗的实践组,每组各33例,对比两组患者的治疗效果。结果显示,普通组患者总治疗率为81.8%(显著15例、改善12例、无效6例)小于实践组的治疗率94.0%(显著18例、改善13例、无效2例)(P<0.05)。治疗之前,实践组与普通组患者在肺功能数值上比较无统计学差异(P>0.05);治疗后,实践组患者用力肺活量(4.02±0.75)L、第一秒呼气量最大数值(2.19±0.53)L,两者比值(71.84±6.31)%,均大于普通组患者的用力肺活量(2.60±0.66)L、第一秒呼气量最大数值(2.81±0.60)L、两者比值(70.22±6.51)%(P<0.05)。在治疗慢性阻塞性肺疾病的过程中使用西洛司特可以明显提高慢性阻塞性肺疾病患者的疗效,更好地调整患者的病情,优化自身肺功能,促进患者早日康复。

The clinical effect of Cilomilast treatment on COPD was observed.66 COPD patients in Heilongjiang Armed Police Corps Hospital from Sep.2017 to Jun.2019 were selected,and they were randomly divided into control group and observation group,with 33 patients in each group.Control group received routine treatment,and the observation group received Cilomilast treatment.The treatment effects of two groups were compared.The total effective rate of control groups was 81.8%(significant in 15 cases,improved in 12 cases and ineffective in 3 cases),which was less than 94.0%in observation group(significant in 18 cases,improved in 13 cases and ineffective in 2 cases)(P<0.05).Before treatment,there was no significant difference of lung function numerical value in observation group and control group(P>0.05).After treatment,force vital capacity was(4.02±0.75)L,the maximum of the first second expiration was(2.19±0.53)L,and the ratio of the two was(71.84±6.31)%in observation group which was higher than(2.60±0.66)L,(2.81±0.60)L and(70.22±6.51)%(P<0.05).Cilomilast can significantly improve the curative effect of COPD,better adjust disease condition,optimize lung function,and improve the recovery.